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Abstract
Background: Array-CGH (aCGH) is presently used into routine clinical practice for diagnosis of patients with
intellectual disability (ID), multiple congenital anomalies (MCA), and autism spectrum disorder (ASD). ACGH
could detect small chromosomal imbalances, copy number variations (CNVs), and closely define their size and
gene content. ACGH detects pathogenic imbalances in 14–20 % of patients with ID. The aims of this study
were: to establish clinical clues potentially associated with pathogenic CNVs and to identify cytogenetic indicators to
predict the pathogenicity of the variants of uncertain significance (VOUS) in a large cohort of paediatric patients.
Methods: We enrolled 214 patients referred for either: ID, and/or ASD and/or MCA to genetic services at the Federico
II University of Naples, Department of Translational Medicine. For each patient we collected clinical and imaging data.
All the patients were tested with aCGH or as first-tier test or as part of a wider diagnostic work-up.
Results: Pathologic data were detected in 65 individuals (30 %) and 46 CNVs revealed a known syndrome. The
pathological CNVs were usually deletions showing the highest gene-dosage content. The positive family history for
ID/ASD/MCA and ASD were good indicators for detecting pathological chromosomal rearrangements. Other clinical
features as eyes anomalies, hearing loss, neurological signs, cutaneous dyscromia and endocrinological problems seem
to be potential predictors of pathological CNVs. Among patients carrying VOUS we analyzed genetic features including
CNVs size, presence of deletion or duplication, genic density, multiple CNVs, to clinical features. Higher gene density
was found in patients affected by ID. This result suggest that higher gene content has more chances to include
pathogenic gene involved and causing ID in these patients.
Conclusion: Our study suggest the use of aCGH as first-tier test in patients with neurdevelopmental phenotypes. The
inferred results have been used for building a flow-chart to be applied for children with ID.
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Background
ID (intellectual disability) and ASD (autism spectrum
disorder) are life-long conditions with deficits in cogni-
tive functioning (IQ<70) and adaptive skills that affects
1–3 % of children worldwide [1]. Array-CGH (aCGH)
offers a high diagnostic yield, ranging from 14–20 %, for
individuals with unexplained ID, ASD or multiple con-
genital anomalies (MCA) [2–5]. Available evidence sug-
gests a change in the diagnostic approach for children
with neuropsychiatric disorders and/or congenital anom-
alies, indicating the aCGH as the first-tier cytogenetic
diagnostic test [5]. In 2014 the SIGU (Italian Society of
Human Genetics) suggested that ID, of all severity, and/
or ASD and/or epilepsy, hypotonia, dysmorphisms,
growth alteration, congenital malformations might be
associated with pathogenic aCGH results.
The chromosomal imbalances detected by aCGH are
defined copy number variations (CNVs) that are referred
as: microdeletions and microduplications of clear clinical
relevance or pathogenic, variants of uncertain signifi-
cance (VOUS) and benign polymorphisms [6–8]. The
advances in molecular methodology of aCGH technol-
ogy, along with its broader application, facilitated the de-
tection of novel pathogenic CNVs. The significance of
many VOUS still remains uncertain causing serious
problems in defining their contribution in patients af-
fected by ID, MCA and ASD [9–13].
The aim of this study was twofold:
1. To determine phenotypic clues associated to
pathogenic CNVs, outlining criteria for selecting
patients to be studied with aCGH as first-line test.
2. To identify cytogenetic criteria of VOUS to be taken
into account for their potentially pathogenicity.
These aims allow us to depict an integrative flow-chart
applying for children with ID.
Study design
We present a retrospective-prospective study including
214 patients. In order to establish which patients could
mostly benefit of aCGH as first molecular test, we tried
to individuate clinical and anamnestic clues that signifi-
cantly correlate with pathologic aCGH data. For this
purpose, all the subjects received a complete history re-
call and an accurate clinical and instrumental evaluation.
All the anamnestic-clinical-investigation data, either as a
single feature or in combination, were correlated to
pathologic or negative aCGH results.
Our second aim was to identify cytogenetic elements
that could predict the pathological role of VOUS. We
characterized meticulously all the VOUS detected, re-
cording: the size of the rearrangements, the presence of
deletions, duplications or multiple rearrangements and
the genic density. We correlated the cytogenetic data
with the severity of the phenotype. A severe phenotype
was defined on the presence of severe ID, ASD and mul-
tiple malformations.
On the basis of inferred results, we define a flow-chart
applying for children with ID.
Patients and methods
Patients
We enrolled 214 patients (114 males and 100 females
with an average age of 5.63 years, range 1.3–19 years),
with or without variable degree of ID, and/or ASD and/
or MCA. They had been referred and evaluated at the
Clinical Genetic Unit of the Translational Medical
Science Department, section of Pediatrics, of the
University of Naples “Federico II” in a 10-year period
(2002–2012): 91 patients were recruited (47 male and 44
female, age range 1.7–19 years, mean 5.1 years) from
2002–2006, and followed up, so belonged to a retro-
spective part of the study; 123 patients (69 male and 54
female, age range 8 month-11years, mean 6.16 years)




The diagnostic workup started with a meticulous family
history recall, physical examination focused on the pres-
ence of minor (dysmorphology evaluation) and major
anomalies, neurological exam and assessment of the be-
havioral phenotype as detailed in the Additional file 1.
Instrumental evaluation
The diagnostic instrumental evaluation included: brain
MRI, abdominal ultrasound, echocardiography, EEG and
ABR. Not all the investigations were performed due to
the lack of patient cooperation or parental consent. For
patients who underwent brain MRI the association be-
tween brain structural anomalies and the presence of ID
(moderate/severe), microcephaly, macrocephaly, hearing
loss, EEG abnormalities was evaluated.
Metabolic screening tests
A metabolic screening panel (plasma amino acids, acyl-
carnitine profile, urine organic acids, ammonia and lac-
tic acid) was performed. Targeted metabolic tests
(lysosomal enzymes, urine oligosaccharides, transferrin
isoform profile, plasma sterol concentrations, congeni-
tal glycosylation defects) were carried out when clinical
suspect arose.
Cytogenetic analysis
For patients included in the retrospective part, initial
tests to exclude genetic syndromes suspected based on
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the facial and gestalt phenotypes or due to initial un-
availability of aCGH were performed, including: karyo-
type (standard and high resolution type), specific loci
(22q11.2, 7q11.23, 16p13.3) and/or subtelomeric FISH,
DNA methylation analysis for Prader-Willi and Angel-
mann syndrome and FRAX-A/E test. Since a diagnosis
was not achieved through these procedures, aCGH with
an average resolution of 500 Kb was performed. In pa-
tients enrolled in the prospective part of the study,
aCGH with a resolution of 50–75 Kb was used as first
tier test. Different platforms have been used along with
progressive improvement of aCGH technology. Despite
this could represent a bias we could not analyze again all
the patients previously studied in the retrospective part
with a lower resolution power. We re-analyzed only few
patients with clinical features strongly suggestive for
chromosomal disorder and showing normal results.
These results have been considered in the prospective
part of the study.
Cytogenetic techniques applied and CNVs interpret-
ative processes are included in Additional file 1.
The CNVs size, the presence of multiple rearrange-
ments and the number of genes located in were assessed.
Patients with overlapping chromosomal rearrangements
have been compared and studied.
Statistical analysis
Clinical data were assessed using a standardized protocol
(excel sheet) for collection of data in all children. SPSS
software (version 20.0; SPSS Inc., Chicago, IL, USA) and
R (version 2.5.0; The R Foundation for Statistical Com-
puting) were used for the statistical analysis. Analyses in-
cluded only available data and missing values were not
imputed. Data were summarized as means ± standard
deviation (median [25th–75th percentile]) for continuous
variables and as frequencies (%) for categorical variables.
The association between the presence of a pathogenic
CNV (as opposed to a normal array CGH results) with
clinical characteristics (including ID, ASD, and familiar-
ity with ID and with several anomalies/malformations)
was based on a standard two-step approach. In particu-
lar, univariate association between each predictor and
the aCGH results were first established using chi-square
test (or the fisher exact test when appropriate); after-
ward, those factors showing a bivariate association with
the dependent variable at a p<0.2 were entered in a
multivariate logistic regression model using a backward
stepwise method for the selection of variables. The dis-
criminatory ability of the final model was assessed using
ROC curve analysis. In order to correct the area under
the ROC curve (AUC) for over-optimism, which occurs
when the fit of a model is evaluated using the same data
in which the model was built, a bootstrap procedure as
described in [14] was used. The exact Mann–Whitney U
test was used for comparing children with and without
ID in case of VOUS with respect to the following vari-
ables: presence of deletions/duplications, number of




In our cohort 168/214 patients showed ID: mild, moder-
ate and severe ID was identified in 129, 25 and 14 pa-
tients respectively. All the clinical findings recorded
along with their frequency are shown in Table 1.
Instrumental evaluation
All the results from instrumental evaluation are pre-
sented in Table 2. Currently, a consensus on the role of
neuroimages in patients with ID has not been achieved.
Brain MRI findings have to be considered of contribu-
tory value but not essential in defining a genetic diagno-
sis or in the assessment of children with ID. Brain MRI
was performed in 122 out 214 patients (57 %) and 57 of
122 (47 %) showed structural malformations in line with
previous report [3]. To date consensus to perform brain
MRI include macrocephaly, microcephaly, asymmetric
neurologic signs, intractable epilepsy or focal seizures,
abnormal movements, hypotonia or progressive neuro-
logical disorder [2, 15]. In our cohort we did not find
any correlation between brain MRI pathological findings
and microcephaly (p= 0.652) or macrocephaly (p=0.473).
Conversely pathologic MRI findings were correlated with
both moderate/severe ID (p=0.046) and neurosensitive
hearing loss (p=0.01).
Metabolic profile
The metabolic screening panel consisting in: plasma
amino acids, acylcarnitine profile, urine organic acids,
ammonia and lactic acid were applied in around 50 % of
patients. In specific cases lysosomal storage disease were
partially ruled out performing lysosomal enzymes assay,
urine oligosaccharides and glycosaminoglycans. Trans-
ferrin isoform profiling and sterols were performed only
in 9 and 6 % of patients (Table 2).
Cytogenetic analysis results
Detection rate
Pathological aCGH results was obtained in 65 patients
(30 males and 35 females) (30 %), 124 patients (58 %)
showed negative results or benign CNVs, while in 25
cases (12 %) VOUS were detected (Fig. 1). Figure 2 sum-
marizes genetic loci of all detected pathogenic CNVs
and VOUS. Pathological CNVs showed the highest
average size of chromosomal rearrangement and gene
content, a higher prevalence of deletions and of multiple
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rearrangements than those detected in VOUS and be-
nign CNVs (Table 3).
Specific syndromes
The diagnosis of already known genetic syndromes was
achieved in 47 patients (data not shown). For Cri-du-
chat syndrome, DiGeorge syndrome, 1q21.1 deletion
syndrome, 1q21.2 deletion syndrome, 3q29 deletion
syndrome, 6p25 deletion syndrome, 6q duplication syn-
drome, 13q12.3 deletion syndrome and 16p11.2 deletion
syndrome, more than one case was recorded. The com-
parison of these cases might widen the phenotype asso-
ciated to microdeletion syndromes and might contribute
to a more careful study of critical regions containing
haplosensitive genes. Furthermore, 18 pathogenic novel
chromosomal rearrangements have been discovered as
well.
Correlation study results
Table 4 shows the distribution of the clinical features
and anomalies/malformations in children with patho-
genic and negative aCGH results. In a univariate ana-
lysis, the only predictive factors of pathologic array
results were: ASD and positive family history for ID/
MCA/ASD. No significant differences in the frequencies
of facial and non-facial dysmorphic features, congenital
anomalies were recorded. ID, dysmorphic eyes
anomalies, conductive and neurosensorial hearing loss,
Table 1 Clinical features recorded in each patient expressed as
percentage in are provided
Signs/symptoms Percentage of patients




Autism spectrum disorder 17.2 %
Familiarity for ID and/or MCA 8 %
Prenatal perinatal problems 14 %
Short stature 19.15 %
Tall stature 2.8 %
Macrocephaly 7 %
Microcephaly (Craniosynostosis included) 31 %
Forehead and eyebrows phenotypic
abnormalities
38 %
Eyes, palpebral fissures and eyelashes
phenotypic abnormalities
54 %
Nose and phyltrum phenotypic abnormalities 37 %
Oral region, teeth and tongue phenotypic
abnormalities
49 %
Ears phenotypic abnormalities 37 %
Neck and thorax phenotypic abnormalities 18 %






Neurology (Epilepsy, hypertonia, hypotonia,
paresis, extrapyramidal signs)
14 %
Cardiac malformations 33 %
Pulmonary malformations 1 %
Kidney and urinary tract anomalies 8 %
Abnormal external genitalia 12 %
Ocular malformation 16 %
Vertebral anomalies 22 %
Skeletal dysplasia 5 %
Haematological abnormalities 3 %
Nails and hair anomalies 13 %
Alterated skin pigmentation or skin
hemangioma
13.3 %
Endocrinological abnormalities 10 %
Table 2 Genetic and Instrumental tests performed in the cohort
are indicated





ABR 39 % 41 %
EEG 37 % 29 %
Brain MRI 47 % 57 %
Karyotype 0 % 71 %
FRAX-A 0 % 26 %
Prader-Willi/Angelman 0 % 6 %
FISH 22q11.2 0 % 6 %
FISH 7q11 0 % 2 %




0 % 6 %
Other molecular
analyses
0 % 21 %
Plasma amino acids
and acylcarnitines
0 % 59 %
Urine organic acids 0 % 46 %
Plasmatic ammonia
and lactic acid
0 % 40 %
Oligosaccharides
(urine)
0 % 13 %
Glycosaminoglycans
(urine)
0 % 11 %
Serum transferrin
isoform profiling
0 % 9 %
Sterols (plasma) 0 % 6 %
Percentages of positive and negative results are pointed out
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neurological signs (epilepsy, hypertonia, hypotonia, and
paresis), cutaneous dyschromia and endocrinological
problems were considered as potential predictors due to
an association with the outcome at a liberal p value of
0.2. A multivariable logistic regression model with
backward selection, showed that ID (OR 2.57; 95 %
CI [1.07–6.2]; p=0.035), familiarity with ID/MCA/ASD
(OR 11.4; 95 % CI [3.21–40.49]; p=<0.001), and cutaneous
dyschromia (OR 2.75; 95 % CI [1.19–6.34]; p=0.018) were
all independent predictors of a pathogenic CNV and
yielded an optimism-corrected estimate of the overall
accuracy, in terms of AUC, of 0.69 (the bootstrap estimate
of the optimism in AUC was very small and equal to
0.01). The Chi-square Hosmer and Lemeshow were equal
to 4.78 with a p value of 0.44. We enrolled 37 patients
with ASD, in presence or absence of ID, 23 males and 14
females. Seventeen showed pathological CNVs and 4
VOUS. 12 patients carried out one or more microduplica-
tions, 9 microdeletions and 2 both microdeletion and
microduplication.
Characterization of uncertain CNV (VOUS)
Different clinical features (as single data or in combin-
ation) were correlated to cytogenetic features of de novo
VOUS (CNVs dimension, presence of deletion vs dupli-
cation, genic density, presence of multiple different
CNVs) (Table 5). We found that in children with ID,
VOUS had a significantly higher gene density than in pa-
tients without ID (p=0.019). No associations were found
between VOUS cytogenetic data and other analyzed
clinical features (ASD, short stature, tall stature, macro-
cephaly, microcephaly, craniosynostosis, hearing loss,
hepatic and gut malformation, brain malformation, epi-
lepsy, heart malformation, genitourinary malformation,
eye malformations, skeletal dysplasias, immunological
anomalies, skin hyper/depigmentation, endocrinological
problems). Moreover the severity of clinical phenotype
did not correlate with any cytogenetic characteristics
shared by VOUS.
Fig. 1 ACGH results are depicted
Fig. 2 Overview of 90 chromosomal imbalances by aCGH (VOUS and pathogenic results included). See Legend for interpretation of markers
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Table 3 Cytogenetic features of detected CNVs
Average size of chromosomal
rearrangement (kb)
Deletions Duplications Gene Content Multiple chromosomal rearrangements
(number of patients)
VOUS (25) 523.30 13 13 2.73 9
Pathological CNV (65) 7018.2 65 42 34.67 29
Benign (26) 364.72 19 25 2.52 11
It should be noticed that pathogenic CNVs shared larger rearrangements, high number of deletions and multiple rearrangements
Table 4 Correlations between single and combined clinical features and pathogenic and negative aCGH results are shown
Clinical signs, dysmorphic features aCGH results (number)
Negative (115) Pathological (60) Overall (175) p
Intellectual Disability 83 (72.2) 49 (81.7) 132 (75.4) 0.166
Autism Spectrum Disorders 13 (11.3) 14 (23.3) 27 (15.4) 0.037
Familiarity for ID/MCA/ASD 3 (2.6) 9 (15) 12 (6.9) 0.002
Prenatal perinatal problems 17 (14.8) 9 (15) 26 (14.9) 0.934
Short stature 21 (18.3) 12 (20) 33 (18.9) 0.781
Tall stature 3 (2.6) 1 (1.7) 4 (2.3) 1.000
Macrocephaly 8 (7) 4 (6.7) 12 (6.9) 1.000
Microcephaly (or craniosynostosis) 30 (26.1) 16 (26.7) 46 (26.3) 0.934
Forehead and Eyebrows dysmorphisms 41 (35.7) 21 (35) 62 (35.4) 0.932
Eyes, palpebral fissures and eyelashes dysmorphisms 53 (46.1) 36 (60) 89 (50.9) 0.081
Nose and philtrum dysmorphisms 40 (34.8) 23 (38.3) 63 (36) 0.642
Oral region, teeth and tongue dysmorphisms 45 (39.1) 28 (46.7) 73 (41.7) 0.337
Ears dysmorphisms 43 (37.4) 24 (40) 67 (38.3) 0.736
Neck and thorax anomalies 21 (18.26) 14 (23.73) 35 (20.11) 0.394
Upper and lower limbs, hands, feet dysmorphisms 24 (20.9) 12 (20) 36 (20.6) 0.893
Hearing Loss 15 (13) 13 (21.7) 28 (16) 0.140
Gastrointestinal malformations 15 (13) 5 (8.3) 20 (11.4) 0.353
Brain Malformations 13 (11.3) 8 (13.3) 21 (12) 0.695
Neurologic signs (Epilepsy, hypertonia, hypotonia, paresis) 15 (13) 4 (6.7) 19 (10.9) 0.198
Cardiac malformations 36 (31.3) 23 (38.3) 59 (33.7) 0.350
Pulmonary malformations 2 (1.7) 1 (1.7) 3 (1.7) 1.000
Kidney and urinary tract anomalies 3 (2.6) 1 (1.7) 4 (2.3) 1.000
Abnormal external genitalia 15 (13) 7 (11.7) 22 (12.6) 0.794
Eye malformations 12 (10.4) 7 (11.7) 19 (10.9) 0.804
Vertebral anomalies 29 (25.8) 14 (23) 43 (24.57) 0.718
Skeletal dysplasia 7 (6.1) 3 (5) 10 (5.7) 1.000
Haematological abnormalities 2 (1.7) 3 (5) 5 (2.9) 0.219
Nails and hair anomalies 16 (13.9) 6 (10.2) 22 (12.6) 0.482
Alterated skin pigmentation 8 (7) 9 (15) 17 (9.7) 0.088
Skin hemangioma 3 (2.6) 1 (1.7) 4 (2.3) 1.000
Endocrinological anomalies 9 (7.8) 9 (15) 18 (10.3) 0.138
Statistical significant correlations exist between pathologic CNVs and ASD and familiarity for ID/ASD/MCA. Other clinical features: ID (independent from severity),
dysmorphisms of eyes, palpebral fissures and eyelashes, Hearing Loss, neurologic signs, abnormal skin pigmentation and endocrinological anomalies) appear to
be potential predictors of pathological aCGH results
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Suggested diagnostic flow-chart
Since ID/ASD/MCA are conditions of great concern and
deserve special care, a flow-chart regarding the most ap-
propriate care for patients with ID (including metabolic
screening test, neuroimaging evaluation, diagnostic mo-
lecular investigations) has been depicted on the basis of
the data inferred from this study (Fig. 3). We matched
the data we obtained with the large-scale studies sharing
a similar aim [16–19]. In the present work we could
not use the combined technology “aCGH and single-
nucleotide polymorphism (SNP) array”. We suggest to
use this combination, when available, to detect CNVs
plus a limited amount of SNP data to screen for absence
of heterozygosity [19].
Discussion
ID is a developmental disability, which presents in
infancy or early childhood characterized by impaired
Table 5 Evaluation of cytogenetic indicator in VOUS suggests that gene density is the only parameter associated to ID
Intellectual disability
Absent (n=4) Mild/Moderate (n=21) Total (n=25) p
Deletion; n (%) 3 (75 %) 10 (47.6 %) 13 (52 %) 0.593
CNV dimension; Median [25th 75th percentile] 367.5 [145.75;801.5] 258 [160.5;791] 258 [160.5;791] 0.902
Genic densitiy; Median [25th 75th percentile] 0.5 [0;1] 2 [1;4.25] 2 [1;3.25] 0.019
Multiple CNVs; Median [25th 75th percentile] 1 [1;2.5] 1 [1;2] 1 [1;2] 0.858
Fig. 3 Algorithm in patients with unexplained ID and/or and/or ASD. After the collection of appropriate clinical and family history, you need to
take a detailed physical and dysmorphology examination. If patient has a recognizable pattern of signs and symptoms you have to confirm
diagnosis by cytogenetic or molecular targeted test. Nonetheless the infrequent detection rate Fragile X A/E syndrome should be excluded
in all patients with ID. If the patient does not present with features of recognizable syndrome or metabolic disorder or the latter resulted
negative for a suspected syndromes aCGH is the first-tier test especially in case of ASD diagnosis or family history positive for ID/MCA/
ASD. Other potential predictors of pathogical results are: ocular anomalies, hearing loss, neurological signs, cutaneous dyscromia and
endocrinological problems. If aCGH comes back negative further clinical investigations are warranted. If the detected CNV includes relevant
region/genes or the gene content and its size meet guidelines criteria the result has to be considered pathogenic. In such cases parental studies and
evaluation of cytogenetic feature as gene density could aid in ascertain their likely pathogenicity
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intellectual functioning and adaptive behavior. The
prevalence is estimated between 1 and 3 % of chil-
dren [5, 20–22]. ASDs are clinically heterogeneous
disorders that include: autism, Asperger syndrome,
pervasive developmental disorders not otherwise spe-
cified, and childhood disintegrative disorder. ASD has
been estimated to affect 1/100 to 1/150 children [3].
Many children with ASD also have ID representing
together the most frequent referral to geneticists for a
diagnostic workup. American Academy of Pediatrics
Committee has discussed the importance of early
identification of the cause of neurocognitive pheno-
type identifying several benefits [3]. Since even small
chromosomal anomalies have been established as a
major cause of ID and ASD, aCGH test has become
an important diagnostic tool for patients at least shar-
ing neuro-phenotypes [2–5].
Despite a very high number of studies describing
genetic findings of CNVs, we identifed a high rate of
pathologic CNVs, more frequently deletions, in a co-
hort of patients with ID and/or ASD. High gene con-
tent is also found in patients with VOUS and ID.
We also demonstrated that a positive family history
for ID/ASD/MCA (cardiologic, renal, intestinal anomal-
ies) and ASD were two good independent indicator of
pathologic CNVs.
On the basis of our data we suggest that aCGH should
be used as first tier diagnostic test in the presence of ID/
ASD/MCA. We also underline the importance of family
historical recall and of parents’ clinical observation in
order to evaluate the presence of ID/ASD in the parents.
Among VOUS, higher gene density was found in
patients affected by ID.
A diagnosis of metabolic disorders has been reported
in 1–5 % of patients with ID [3, 19, 23, 24]. Diagnostic
evaluation for inborn errors of metabolism (IEMs) was
performed in 126 patients giving normal data. Notwith-
standing, metabolic studies should be thoroughly consid-
ered in patients with ID due to the potential treatability
of IEMs.
ACGH was performed in patients included in the retro-
spective part of this study because of negative results of
other genetic studies, while it was applied as first tier test
in the prospective part of the study because growing num-
ber of papers highlighted its diagnostic power [25–27].
We identified 65 (30 %) and 25 (12 %) patients with
pathogenic CNVs and VOUS respectively. The detection
rate of clinically significant CNVs is about 30 % therefore
higher than the yields (from 14.2–21.1 %) obtained from
studies that used similar platforms [2, 3, 5, 10, 28–30]. We
speculate that the higher prevalence of pathological CNVs
in our study is potentially ascribed to the careful selection
of patients. Among patients with pathological CNVs, the
deletions were more frequent than duplications (65 vs 42)
being the former more commonly interpreted as
pathogenic [10]. The pathogenic CNVs have a higher
size (7 Mb) and gene density (35 genes) than VOUS
and benign ones in agreement with other reports [29,
31, 32]. 29 patients with pathological CNVs have mul-
tiple rearrangements, which are known to exacerbate
neuro-developmental phenotypes (Table 3) [5, 32]. In
these patients parental chromosomal study did not re-
veal balanced translocations.
We diagnosed 47 patients (22 %) with OMIM syn-
dromes on the basis of either overlapping described
well- microdeletion/microduplication syndromes or
known causing-genes mapped within chromosomal rear-
rangements. ACGH detected CNVs scattered throughout
the genome, but the chromosome 1, 8, 22, X resulted
most frequently involved in line with other reports [33].
The non-random involvement of specific chromosomal
segments could be the results of non-allelic homologous
recombinant mutational mechanism [29]. Other recur-
rent pathogenic CNVs involved 1q21.1, 1q41q42, 2p15,
16p13.1, 16p11.2, 17q21.31 allowing us to characterize
the phenotypes associated to chromosomal rearrange-
ments in these specific regions [30, 34–39]. A specific
chromosomal abnormality does not always correspond
to a specific or suggestive phenotype. In such cases, the
detection of genomic aberration precedes the definition
of specific phenotypes [30]. In our dataset patients with
22q11.21 deletion and Cri-du-chat syndromes showed
an atypical phenotype making the clinical diagnosis
challenging [40].
The potential limitations of aCGH application regard:
delayed turnaround time, the impossibility of the detec-
tion of balanced translocations and low-level mosai-
cisms, the high costs, so that clinical criteria for
selection of patients with higher probability of patho-
genic CNV are desirable.
The selection of patients who are most likely to have a
diagnosis by aCGH, minimizing the number of benign
CNVs or negative results, remains an attractive goal
[41]. This study represents the largest collection of
specific clinical and instrumental data for which an
association with pathologic CNVs has been investigated.
From previous studies, the same rate of pathologic
chromosomal imbalances by aCGH was found in unse-
lected and selected patients ([18, 41] respectively). Other
studies found the higher frequency of pathogenic CNVs
in patients with congenital anomalies, unspecified dys-
morphisms, growth anomalies, heart defects, primary
microcephaly and familial occurrence of ID [22, 42–44].
The diagnostic yield among patients with more severe
ID would be expected to be higher than in patients with
milder ID [45–47]. In our cohort, 47 patients were en-
rolled because of MCA and they did not show ID. In-
deed pooling data from patients with different ID degree
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and without ID, we conclude that more severe ID is not
statistically related to pathogenic CNVs [4, 5, 29].
Among the consistent number of clinical and history
data analyzed, positive family history for ID/MCA/ASD
and isolated ASD were found to be associated to patho-
logical aCGH results. We would underline that other
congenital anomalies as ocular dysmorphisms (p=0.062),
hearing loss (p=0.127), neurological signs (p=0.103), cu-
taneous dyscromia (p=0.08) and endocrinological system
involvement (p=0.128) are potentially predictors of
pathological CNVs.
In this cohort, 37 patients were affected by ASD. The
overall diagnostic yield of aCGH for patients with ASD
ranges from 18.2–22 % [45, 48–50]. In our cohort the
diagnostic yield is consistently greater (around 44 %, 16
patients out 37). Among ASD patients of this case-study,
pathogenic CNVs are mostly located at chromosome 1,
4, 6, 8, 21 and 22, that partially confirm the previous re-
sults from the literature [45, 51]. In the present study we
found a low frequency of abnormal FRAX-A test results
as previously described [19].
Some hesitations in using aCGH in clinical setting diag-
nostic test derive from the difficulties in the efficient dis-
crimination between benign, VOUS and pathogenic CNVs
[2, 11, 52]. CNVs can be interpreted as abnormal (patho-
logical CNVs), VOUS and benign. We interpreted CNVs
as pathogenic when contained: critical regions of microde-
letion/microduplication known syndromes, genes associ-
ated with autosomal dominant inherited diseases and
when cases with similar phenotypes and overlapping
CNVs have already reported. CNVs are likely to be benign
if they are reported in controls databases (similar CNVs in
at least three healthy individuals in the same “sense”, with
an overlap of more than the 50 % and the not-overlapped
part less than 100 Kb), if they do not contain genes and/or
known regulatory elements. Comparative analysis, with
data listed in available large datasets, guide toward the
clarification of CNVs clinical impact and interpretation.
Multiple sources were considered as level of docu-
mentation. All the identified CNVs have been com-
pared to those listed in: the Database of Genomic
Variants (DGV, http://projects.tcag.ca/variation) that
includes healthy individuals, the pathogenic CNVs da-
tabases for patients with ID, ASD and MCA: as the
International Standard Cytogenomic Array Consor-
tium Databases (ISCA, https://www.clinicalgenome.or),
as well as the Database of Chromosomal Imbalance
and Phenotype in Humans using Ensemble Resources
(DECIPHER, https://decipher.sanger.ac.uk/). The Data-
base of Genomic Structural Variation (dbVar, http://
www.ncbi.nlm.nih.gov/dbvar) including structural variation
from both normal control population and disease
population has been consulted as well. The genes,
involved in the chromosomal region of interest, and
their functions have been checked by UCSC Genome
Browser (http:// http://genome-euro.ucsc.edu/cgi-bin/
hgGateway) and Ensamble Genome Browser (http://
www.ensembl.org/index.html). In the interpretative
process, each gene, within the CNV as well as neighboring
genes, was studied for its potential role in neurological de-
velopment, by all the available evidence along sources as
OMIM, Genereviews, PubMed. The CNVs not associated
with previously reported pathogenicity or benignity criteria
were estimated as VOUS. The potential pathogenicity of
VOUS is reported to be determined by many factors: the
“sense” of the rearrangement (deletion or duplication, as
the penetrance of duplications is considered lower than of
deletions), the size (pathogenic imbalances tend to be larger
than benign) and the gene content [7]. We detected and
analyzed 25 de novo VOUS and evaluated some cytogen-
etic indicators: overall size, gain vs loss, presence of mul-
tiple rearrangements (complex rearrangements involving
several CNVs) and gene content. Only gene content had a
significant correlation with ID. The gene content should be
evaluated in order to speculate the pathogenicity of VOUS
[7, 10, 53].
Due to presence of VOUS, incomplete penetrance, and
variable expressivity of CNVs the role of genetic counseling
in aCGH testing and CNVs interpretation complements
the diagnostic testing. Moreover pre-test counseling cannot
be underestimated and should review potential benefits and
limitations of the test.
Conclusion
The achievement of a specific genetic diagnosis im-
proves medical care and allows an accurate recurrent
risk counselling for the family. ACGH enables: discover-
ing emerging new syndromes and variable presentations
of already characterized ones, deciphering the genetic
bases of many syndromes by discovering candidate
genes. The current study highlights that a checklist of
clinical features for preselecting cases for aCGH analysis
with high sensitivity and specificity is difficult to attain.
The positive family history for ID/MCA/ASD and the
presence of ASD seem to be independent additional
clues positively associated to causative CNVs. Among
other criteria, ID (with no correlation with the level),
eyes anomalies, hearing loss and other neurological
signs, cutaneous dyscromia, endocrinological system
involvement were also deemed as potentially predict-
ive factor of pathogenic CNVs. VOUS involving gene-
rich regions are more frequently associated to ID and
pathological phenotypes.
What’s Known on This Subject
Array-CGH has been defined the first line diagnostic tool
in patients sharing intellectual disability and multiple
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congenital abnormalities. The diagnostic yield is still low
and interpretative issues of the results remain elusive.
What This Study Adds
Phenotypic clues predictive of pathological results have
been defined to help in patients’ selection to be studied
with array-CGH. Cytogenetic features of rearrangements
to be taken into account are provided; variant of uncertain
significance showed higher density in patients sharing
intellectula disability. A revised flow-chart for patients
with intellectual disability is depicted.
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